Cardiol Therapeutics Inc. ( CRDL) Stock. Should you Buy or Sell? $ 1.15
-0.02 (-1.77 %)
Cardiol Therapeutics Inc. Analysis
Updated on 10-09-2022| Symbol | CRDL |
| Price | $1.15 |
| Beta | 0.924 |
| Volume Avg. | $147.66 thousand |
| Market Cap | $71.23 M |
| 52 Week Range | $1.0 - $4.96 |
Cardiol Therapeutics Inc. opened the day at $1.15 which is -1.77 % on yesterday's close. Cardiol Therapeutics Inc. has a 52 week high of $4.96 and 52 week low of $1.0, which is a difference of $3.96. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $71.23 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Cardiol Therapeutics Inc. for $71.23 M, it would take 15 years to get your money back. Cardiol Therapeutics Inc. are in the Drug Manufacturers—Specialty & Generic space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Cardiol Therapeutics Inc. Stock Forecast - Is Cardiol Therapeutics Inc. a Buy or Sell?
| DCF Score | ||
| ROE Score | ||
| ROA Score | ||
| DE Score | ||
| PE Score | ||
| PB Score | ||
| Overall Recommendation |
Growth and Value
| PE Ratio | 0.000 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Cardiol Therapeutics Inc.
| Price Book Value Ratio | 0.000 | Price To Book Ratio | 0.000 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | 0.000 |
How liquid is Cardiol Therapeutics Inc.
| Current Ratio | 0.000 |
| Quick Ratio | 0.000 |
Debt
| Debt Ratio | 0.000 | Debt Equity Ratio | 0.000 |
| Long Term Debt To Capitalization | 0.000 | Total Debt To Capitalization | 0.000 |
Latest news about Cardiol Therapeutics Inc.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc. announced that the first patient has been enrolled in ARCHER, a Phase 2 trial designed to study the safety and tolerability of the oral cannabinoid formulation CardiolRx in patients with acute myocarditis.
Oakville, Ontario--(Newsfile Corp. - June 27, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), is pleased to announce that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 28, 2022, at 4:30 p.m. EDT. Cardiol Therapeutics 2022...
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc., the clinical-stage life sciences company, said it has appointed Teri Loxam and its chief financial officer Chris Waddick to serve as board directors, effective immediately. Loxam has over 25 years of experience in the pharmaceutical, life sciences, and entertainment industries, while Waddick has over 30 years of experience in financial and executive roles in the biotechnology and energy industries, the company said.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc announced that the US Food and Drug Administration has authorized its Investigational New Drug Application to start its Phase II open-label pilot study. The study will evaluate the tolerance and safety of Cardiol's lead drug CardiolRx, a pharmaceutically-manufactured oral cannabidiol formulation for patients with recurrent pericarditis.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc CEO David Elsley told investors that the clinical-stage life sciences company is “well positioned” to pursue the development of new treatment options for patients living with heart disease. In a look back at its 2021 year, Elsley said the firm accomplished “several important goals” related to the development of its pharmaceutically produced cannabidiol formulations for use as an anti-fibrotic and anti-inflammatory therapy in cardiovascular disease.
About Cardiol Therapeutics Inc.
Description :
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
